2022
The grant will accelerate the development of FG001 in the treatment of less malignant brain cancers to the benefit of more patients...
The board of directors of FluoGuide has, based on the authorization granted by the annual general meeting on 9 February 2021, and as...
10 March, 2022
FluoGuide intends to carry out a directed share issue of approximately SEK 25 million
The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuilding...
2021
22 December, 2021
FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer
Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in lung cancer in collaboration with...
19 November, 2021
ABG Sundal Collier initiates equity research on FluoGuide
Starting today, ABG has initiated its equity research, meaning that ABG will continuously monitor and analyze FluoGuide’s operations...
*) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number...
10 November, 2021
FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022
FluoGuide now broadens the clinical potential for fluorescence-guided cancer surgery with FG001 to include the first prevalent indication...
9 November, 2021
Publication of a case report showing first promising clinical data on FG001s use in treatment of meningioma brain tumor
FG001 is currently in clinical investigation at Rigshospitalet, Denmark in a phase I/II trial in patients with High Grade Glioma undergoing...
5 November, 2021
Financial calendar 2022 for FluoGuide, and release of the Q3 report 2021 is moved to 15[th] of November 2021
Financial calendar for 2022 The planned release of the Q3 financial report 2021 is moved from 24th November to 15th November 2021...